跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
CD19/CD20 CAR-T
首页
药物
CD19/CD20 CAR-T
CD19/CD20 CAR-T
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
BISPECIFIC OR-GATE CHIMERIC ANTIGEN RECEPTOR RESPONSIVE TO CD19 AND CD20
EP 3240805 B1
申请人: UNIV CALIFORNIA
优先权: 2014
EP
US
WO
16 件公开
Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof
US 11207349 B2
申请人: CELLULAR BIOMEDICINE GROUP HK LTD
优先权: 2020
CN
EP
US
WO
15 件公开
CD20 THERAPIES, CD22 THERAPIES, AND COMBINATION THERAPIES WITH A CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) - EXPRESSING CELL
EP 3280729 B1
申请人: NOVARTIS AG
优先权: 2015
CN
EP
US
WO
14 件公开
CHIMERIC ANTIGEN RECEPTORS AND CAR-T CELLS AND METHODS OF USE
EP 3893899 A2
申请人: KITE PHARMA INC
优先权: 2018
CN
EP
US
12 件公开
CAR T CELLS FOR TREATING CD19+, CD20+ OR CD22+ TUMORS OR B-CELL DERIVED AUTO-IMMUNE DISEASES
EP 4259650 A1
申请人: OSPEDALE PEDIATRICO BAMBINO GESÙ
优先权: 2020
CN
EP
US
WO
4 件公开
IMMUNE EFFECTOR CELL AND USE THEREOF
EP 4714981 A1
申请人: CARSGEN LIFE SCIENCES CO LTD
优先权: 2023
CN
EP
WO
4 件公开
Bispecific chimeric antigen receptor based on variable domains of heavy chain of heavy-chain antibody and application thereof
CN 105384825 A
申请人: NANJING LEGEND BIOTECHNOLOGY CO LTD
优先权: 2015
CN
Transformation, multiplication culture and preservation method for T cell for expressing CD19 and CD20 antibody gene CAR (chimeric antigen receptor)
CN 106701827 A
申请人: LIU XIAOMING
优先权: 2016
CN
Multi-target combined CAR (chimeric antigen receptor)-T cell preparation and preparation method
CN 106822184 A
申请人: LIANG AIBIN
优先权: 2016
CN
一种基于OCTS技术的淋系白血病CAR-T治疗载体及其构建方法和应用
CN 107245500 B
申请人: 上海优卡迪生物医药科技有限公司
优先权: 2017
CN
第 1 / 4 页
上一页
下一页
药物
反馈